Onset and durability of pain relief in knee osteoarthritis: Pooled results from two placebo trials of naproxen/esomeprazole combination and celecoxib

References

• National Clinical Guideline Center. London: National Institute for Health and Care Excellence (UK). 2014. Available from http://www.nice.org.uk/guidance/cg177/resources/guidance-osteoarthritis-pdf. Last accessed 24 January 2015
   Google Scholar
• Fernandes L, Hagen KB, Bijlsma WJ, Andreassen O, Christensen P, Conaghan PG, et al. EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis. Ann Rheum Dis 2013;72:1125–35
   PubMed Web of Science ®Google Scholar
• Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2163–96
   PubMed Web of Science ®Google Scholar
• Jordan J, Helmick CG, Renner JB, Luta G, Dragomir AD, Woodard J, et al. Prevalence of knee symptoms and radiographic and symptomatic knee osteoarthritis in African Americans and caucasians: the johnston county osteoarthritis project. J Rheumatol 2007;34:172–80
   PubMed Web of Science ®Google Scholar
• Conaghan PG, Peloso PM, Everett SV, Rajagopalan S, Black CM, Mavros P, et al. Inadequate pain relief and large functional loss among patients with knee osteoarthritis: evidence from a prospective multinational longitudinal study of osteoarthritis real-world therapies. Rheumatology (Oxford) 2015;54:270–7
   PubMed Web of Science ®Google Scholar
• American College of Rheumatology Ad Hoc Group on Use of Selective and Nonselective Nonsteroidal Antiinflammatory Drugs. Recommendations for use of selective and nonselective nonsteroidal antiinflammatory drugs: an American College of Rheumatology white paper. Arthritis Rheum 2008;59:1058–73
   PubMed Web of Science ®Google Scholar
• Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American college of rheumatology subcommittee on osteoarthritis guidelines. Arthritis Rheum 2000;43:1905–15
   PubMed Web of Science ®Google Scholar
• McGettigan P, Henry D. Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries. PLoS Med 2013;10:e1001388
   PubMed Web of Science ®Google Scholar
• Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 1987;82:1153–8
   PubMed Web of Science ®Google Scholar
• Massó González EL, Patrignani P, Tacconelli S, García Rodríguez LA. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum 2010;62:1592–601
   PubMed Web of Science ®Google Scholar
• García Rodríguez LA, Barreales Tolosa L. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology 2007;132:498–506
   PubMed Web of Science ®Google Scholar
• Lanza FL, Chan FK, Quigley EMM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009;104:728–38
   PubMed Web of Science ®Google Scholar
• Balmaceda CM. Clinical trial data in support of changing guidelines in osteoarthritis treatment. J Pain Res 2014;7:211–18
   PubMed Web of Science ®Google Scholar
• Balmaceda CM. Evolving guidelines in the use of topical nonsteroidal anti-inflammatory drugs in the treatment of osteoarthritis. BMC Musculoskelet Disord 2014;15:27
   PubMed Web of Science ®Google Scholar
• Bruyère O, Cooper C, Pelletier JP, Branco J, Luisa Brandi M, Guillemin F, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the european society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO). Semin Arthritis Rheum 2014;44:253–63
   PubMed Web of Science ®Google Scholar
• Nelson AE, Allen KD, Golightly YM, Goode AP, Jordan JM. A systematic review of recommendations and guidelines for the management of osteoarthritis: The Chronic Osteoarthritis Management Initiative of the U.S. Bone and Joint Initiative. Semin Arthritis Rheum 2014;43:701–12
   PubMed Web of Science ®Google Scholar
• Rosemont IL. Treatment of osteoarthritis of the knee evidence-based guideline, 2nd edition. J Am Acad Orthop Surg 2013;21:571–6
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, et al. American College of Rheumatology. American college of rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012;64:465–74
   PubMed Web of Science ®Google Scholar
• McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra SM, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage 2014;22:363–88
   PubMed Web of Science ®Google Scholar
• Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62:1145–55
   PubMed Web of Science ®Google Scholar
• Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA; American Heart Association. Use of nonsteroidal antiinflammatory drugs, an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007;115:1634–42
   PubMed Web of Science ®Google Scholar
• Coxib and traditional NSAID Trialists’ (CNT) Collaboration. Bhala N, Emberson J, Merhi A, Abramson S, Arber N, et al. Vascular and upper GI effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomized trials. Lancet 2013;382:769–79
   PubMed Web of Science ®Google Scholar
• Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics–2014 update: a report from the American Heart Association. Circulation 2014;129:e28–e292
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Fort JG, Svensson O, Hwang C, Sostek M. Fixed-dose combination of enteric-coated naproxen and immediate-release esomeprazole has comparable efficacy to celecoxib for knee osteoarthritis: two randomized trials. Curr Med Res Opin 2011;27:1243–53
   PubMed Web of Science ®Google Scholar
• Essex MN, Bhadra P, Sands GH. Efficacy and tolerability of celecoxib versus naproxen in patients with osteoarthritis of the knee: a randomized, double-blind, double-dummy trial. J Int Med Res 2012;40:1357–70
   PubMed Web of Science ®Google Scholar
• Richy F, Bruyere O, Ethgen O, et al. Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis 2004;63:759–66
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. Br Med J 2005;330:1336
   Google Scholar
• Gimenez S, Armada B, Iturralde Iriso J, Ginel Mendoza L, Fernández-Morales B. Clinical management of patients with hip and knee osteoarthritis: patient satisfaction with treatment switch. Rheumatol Int 2014;34:823–32
   PubMed Web of Science ®Google Scholar
• Bannuru RR, Schmid CH, Kent DM, Vaysbrot EE, Wong JB, McAlindon TE. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis. Ann Intern Med 2015;162:46–54
   PubMed Web of Science ®Google Scholar
• Abraham NS, El-Serag HB, Johnson ML, Hartman C, Richardson P, Ray WA, Smalley W. National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs. Gastroenterol 2005;129:1171–8
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Howard KB, Walton SB, McLaughlin TP, Kruzikas DT. Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications. Clin Gastroenterol Hepatol 2006;4:1337–45
   PubMed Web of Science ®Google Scholar
• van Soest EM, Sturkenboom MC, Dieleman JP, Verhamme KM, Siersema PD, Kuipers EJ. Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage. Aliment Pharmacol Ther 2007;26:265–75
   PubMed Web of Science ®Google Scholar
• Cryer BL, Sostek MB, Fort JG, Svensson O, Hwang C, Hochberg MC. A fixed-dose combination of naproxen and esomeprazole magnesium has comparable upper gastrointestinal tolerability to celecoxib in patients with osteoarthritis of the knee: results from two randomized, parallel-group, placebo-controlled trials. Ann Med 2011;43:594–605
   PubMed Web of Science ®Google Scholar
• VIMOVO® prescribing information. Deerfield, IL: Horizon Pharma USA, Inc.; 2014. Available from http://www.vimovo.com/pi/. Last accessed 29 January 2015]
   Google Scholar
• Sostek MB, Fort JG, Estborn L, Vikman K. Long-term safety of naproxen and esomeprazole magnesium fixed-dose combination: phase III study in patients at risk for NSAID-associated gastric ulcers. Curr Med Res Opin 2011;27:847–54
   PubMed Web of Science ®Google Scholar
• Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833–40
   PubMed Web of Science ®Google Scholar
• Bellamy N, Campbell J, Stevens J, Pilch L, Stewart C, Mahmood Z. Validation study of a computerized version of the Western Ontario and McMaster Universities VA3.0 Osteoarthritis Index. J Rheumatol 1997;24:2413–15
   PubMed Web of Science ®Google Scholar
• Bellamy N. WOMAC: a 20-year experiential review of a patient-centered self-reported health status questionnaire. J Rheumatol 2002;29:2473–6
   PubMed Web of Science ®Google Scholar
• Moskowitz RW, Sunshine A, Brugger A, Lefkowith JB, Zhao WW, Geis GS. American pain society pain questionnaire and other pain measures in the assessment of osteoarthritis pain: a pooled analysis of three celecoxib pivotal studies. Am J Ther 2003;10:12–20
   PubMedGoogle Scholar
• Castrejón I, Bergman MJ, Pincus T. MDHAQ/RAPID3 to recognize improvement over 2 months in usual care of patients with osteoarthritis, systemic lupus erythematosus, spondyloarthropathy, and gout, as well as rheumatoid arthritis. J Clin Rheum 2013;19:169–74
   PubMed Web of Science ®Google Scholar
• Pham T, van der Heijde D, Lassere M, Altman RD, Anderson JJ, Bellamy N. Outcome variables for osteoarthritis clinical trials: the OMERACT-OARSI set of responder criteria. J Rheumatol 2003;30:1648–54
   PubMed Web of Science ®Google Scholar
• Pincus T. Pain, function, and RAPID scores: vital signs in chronic diseases, analogous to pulse and temperature in acute diseases and blood pressure and cholesterol in long-term health. Bull NYU Hosp Jt Dis 2008;66:155–65
   PubMedGoogle Scholar
• Pincus T, Yazici Y, Bergman M. A practical guide to scoring a multi-dimensional health assessment questionnaire (MDHAQ) and routine assessment of patient index data (RAPID) scores in 10-20 seconds for use in standard clinical care, without rulers, calculators, websites or computers. Best Pract Res Clin Rheumatol 2007;21:755–87
   PubMed Web of Science ®Google Scholar
• Pincus T, Askanase AD, Swearingen CJ. A multi-dimensional health assessment questionnaire (MDHAQ) and routine assessment of patient index data (RAPID3) scores are informative in patients with all rheumatic diseases. Rheum Dis Clin North Am 2009;35:819–27
   PubMed Web of Science ®Google Scholar
• Pincus T, Castrejón I. MDHAQ/RAPID3 scores: quantitative patient history data in a standardized “scientific” format for optimal assessment of patient status and quality of care in rheumatic diseases. Bull NYU Hosp Jt Dis 2011;69:201–14
   PubMedGoogle Scholar
• Pincus T. RAPID3, an index of only 3 patient self-report core data set measures, but not ESR, recognizes incomplete responses to methotrexate in usual care of patients with rheumatoid arthritis. NYU Hosp Jt Dis 2013;71:17–20
   Google Scholar
• Bjordal JM, Ljunggren AE, Klovning A, Slørdal L. Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials. BMJ 2004;329:1317
   PubMed Web of Science ®Google Scholar
• Bjordal JM, Klovning A, Ljunggren AE, Slørdal L. Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: A meta-analysis of randomised placebo-controlled trials. Eur J Pain 2007;11:125–38
   PubMed Web of Science ®Google Scholar
• Stam WB, Jansen JP, Taylor SD. Efficacy of etoricoxib, celecoxib, lumiracoxib, non-selective NSAIDs, and acetaminophen in osteoarthritis: a mixed treatment comparison. Open Rheum J 2012;6:6–20
   PubMedGoogle Scholar
• Tubach F, Ravaud P, Baron G, Falissard B, Logeart I, Bellamy N, et al. Evaluation of clinically relevant states in patient reported outcomes in knee and hip osteoarthritis: the patient acceptable symptom state. Ann Rheum Dis 2005;64:34–7
   PubMed Web of Science ®Google Scholar
• Pincus T, Yazici Y, Castrejón I. Pragmatic and scientific advantages of MDHAQ/RAPID3 completion by all patients at all visits in routine clinical care. Bull NYU Hosp Jt Dis 2012;70:30–6
   PubMedGoogle Scholar